+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 90Years
All Genders
ID07439211

Evaluating the Safety of PI3K-gamma Inhibitor Eganelisib with Azacitidine and Venetoclax in Treating Acute Myeloid Leukemia

Led by Jacqueline Garcia, MD · Updated on 2026-08-26

48

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and preliminary effectiveness of adding eganelisib, a PI3K-gamma inhibitor, to the standard treatment of venetoclax and azacitidine in adults with acute myeloid leukemia AML. This phase 1 trial aims to find the maximum tolerated dose of eganelisib and confirm the recommended dose for further studies. The FDA has approved azacitidine and venetoclax for AML, but not the combination including eganelisib. Participants will receive treatment cycles lasting 28 days, with azacitidine given on days 1 to 7, and venetoclax and eganelisib taken orally days 1 to 28. The trial includes two parts dose escalation to find the right dose of eganelisib, followed by dose expansion at that dose. After treatment ends, participants will have follow-up visits every 4 months for up to one year to monitor survival. During the study, participants will have screening, clinic visits, blood and urine tests, ECGs, and bone marrow biopsies. Researchers will measure the recommended phase 2 dose, monitor adverse events, and assess remission rates and duration. This study is expected to last about two years, with ongoing safety and efficacy assessments throughout and after treatment.

CONDITIONS

Brief Title

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

Research Team

J

Jaqueline Garcia, MD

J

Jacqueline Garcia, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here